Mineralocorticoid receptor p.l180V polymorphism: Association with body mass index and LDL-cholesterol levels

Journal of Endocrinological Investigation

Volumn 33, Issue 7, 2010, Pages 472-477

  Fernandes Rosa, F L ^a   Bueno, A C ^a   Molina De Souza, R ^a   De Castro, M ^a   Ernesto Dos Santos, J ^a   Foss, M C ^a   Zennaro, M C ^b,c,d,e   Bettiol, H ^a   Barbieri, M A ^a   Antonini, S R ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b PARIS CARDIOVASCULAR RESEARCH CENTER   (France)

^c Centre de Recherche Interdisciplinaire en Biologie   (France)

^d UNIVERSITÉ PARIS DESCARTES   (France)

^e HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

Author keywords

Cardiometabolic risk; Hypertension; Mineralocorticoid receptor; Obesity; Polymorphism

Indexed keywords

BIOCHEMICAL MARKER; CHOLESTEROL; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MINERALOCORTICOID RECEPTOR; TRIACYLGLYCEROL;

ADIPOCYTE; ADULT; ANTHROPOMETRY; ARTICLE; BODY MASS; CARDIOVASCULAR RISK; CASE CONTROL STUDY; CHOLESTEROL BLOOD LEVEL; COHORT ANALYSIS; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; GENE FREQUENCY; GENETIC ASSOCIATION; GENOTYPE; GLUCOSE BLOOD LEVEL; HIP; HUMAN; HYPERTENSION; INSULIN BLOOD LEVEL; MAJOR CLINICAL STUDY; SINGLE NUCLEOTIDE POLYMORPHISM; SYSTOLIC BLOOD PRESSURE; TRIACYLGLYCEROL BLOOD LEVEL; WAIST CIRCUMFERENCE;

ADULT; BODY MASS INDEX; CASE-CONTROL STUDIES; CHOLESTEROL, LDL; COHORT STUDIES; FEMALE; GENE FREQUENCY; HUMANS; HYPERTENSION; MALE; POLYMORPHISM, GENETIC; RECEPTORS, MINERALOCORTICOID; RISK FACTORS;

EID: 77957282689     PISSN: 03914097     EISSN: 17208386     Source Type: Journal    
DOI: 10.3275/6718     Document Type: Article

References (40)

1. Zennaro MC, Lombès M. Mineralocorticoid resistance. Trends Endocrinol Metab 2004, 15: 264-70.
2. Verrey F, Pearce D, Pfeiffer R, et al. Pleiotropic action of aldosterone in epithelia mediated by transcription and post-transcription mechanisms. Kidney Int 2000, 57: 1277-82.
3. Geller DS. Mineralocorticoid resistance. Clin Endocrinol (Oxf) 2005, 62: 513-20.
4. Riepe FG, Finkeldei J, de Sanctis L, et al. Elucidating the underlying molecular pathogenesis of NR3C2 mutants causing autosomal dominant pseudohypoaldosteronism type 1. J Clin Endocrinol Metab 2006, 91: 4552-61.
5. Fernandes-Rosa FL, de Castro M, Latronico AC, et al. Recurrence of the R947X mutation in unrelated families with autosomal dominant pseudohypoaldosteronism type 1: evidence for a mutational hot spot in the mineralocorticoid receptor gene. J Clin Endocrinol Metab 2006, 91: 3671-5.
6. Sartorato P, Lapeyraque AL, Armanini D, et al. Different inactivating mutations of the mineralocorticoid receptor in fourteen families affected by type I pseudohypoaldosteronism. J Clin Endocrinol Metab 2003, 88: 2508-17.
7. Geller DS, Rodriguez-Soriano J, Vallo Boado A, et al. Mutations in the mineralocorticoid receptor gene cause autosomal dominant pseudohypoaldosteronism type I. Nat Genet 1998, 19: 279-81.
8. Geller DS, Farhi A, Pinkerton N, et al. Activating mineralocorticoid receptor mutation in hypertension exacerbated by pregnancy. Science 2000, 289: 119-23.
9. Lifton RP. Molecular genetics of human blood pressure variation. Science 1996, 272: 676-80.
10. Wilson FH, Disse-Nicodème S, Choate KA, et al. Human hypertension caused by mutations in WNK kinases. Science 2001, 293: 1107-12.
11. Freitas SR, Cabello PH, Moura-Neto RS, et al. Analysis of renin-angiotensin-aldosterone System gene polymorphisms in resistant hypertension. Braz J Med Biol Res 2007, 40: 309-16.
12. Tobin MD, Raleigh SM, Newhouse S, et al. Association of WNK1 gene polymorphisms and haplotypes with ambulatory blood pressure in the general population. Circulation 2005, 112: 3423-9.
13. Su YR, Menon AG. Epithelial sodium channels and hypertension. Drug Metab Dispos 2001, 29: 553-6.
14. Mottl AK, Shoham DA, North KE. Angiotensin II type 1 receptor polymorphisms and susceptibility to hypertension: A HugE review. Genet Med 2008, 10: 560-74.
15. Moraes CF, Souza ER, Souza VC, et al. A common polymorphism in the renin angiotensin system is associated with differential outcome of antihypertensive pharmacotherapy prescribed to Brazilian older women. Clin Chim Acta 2008, 396: 70-5.
16. Conen D, Glynn RJ, Buring JE, et al. Association of renin-angiotensin and endothelial nitric oxide synthase gene polymorphisms with blood pressure progression and incident hypertension: prospective cohort study. J Hypertens 2008, 26: 1780-6.
17. Rocha R, Funder JW. The pathophysiology of aldosterone in the cardiovascular system. Ann NY Acad Sci 2002, 970: 89-100.
18. Nagase M, Matsui H, Shibata S, et al. Salt-induced nephropathy in obese spontaneously hypertensive rats via paradoxical activation of the mineralocorticoid receptor: role of oxidative stress. Hypertension 2007, 50: 877-83. (Pubitemid 350287529)
19. Zennaro MC, Le Menuet D, Viengchareun S, et al. Hibernoma development in transgenic mice identifies brown adipose tissue as a novel target of aldosterone action. J Clin Invest 1998, 101: 1254-60.
20. Viengchareun S, Penfomis P, Zennaro MC, et al. Mineralocorticoid and glucocorticoid receptors inhibit UCP expression and function in brown adipocytes. Am J Physiol Endocrinol Metab 2001, 280: 640-9.
21. Caprio M, Fève B, Claës A, et al. Pivotal role of the mineralocorticoid receptor in corticosteroid-induced adipogenesis. FASEB J 2007, 21: 2185-94. (Pubitemid 47026453)
22. Arai K, Nakagomi Y, Iketani M, et al. Functional polymorphisms in the mineralocorticoid receptor and amirolide-sensitive sodium channel genes in a patient with sporadic pseudohypoaldosteronism. Hum Genet 2003, 112: 91-7.
23. DeRijk RH, Wüst S, Meijer OC, et al. A common polymorphism in the mineralocorticoid receptor modulates stress responsiveness. J Clin Endocrinol Metab 2006, 91: 5083-9.
24. Cardoso VC, Simões VM, Barbieri MA, et al. Profile of three Brazilian birth cohort studies in Ribeirão Preto, SP and São Luís, MA. Braz J Med Biol Res 2007, 40: 1165-76.
25. Barbieri MA, Bettiol H, Silva AA, et al. Health in early adulthood: the contribution of the 1978/79 Ribeirão Preto birth cohort. Braz J Med Biol Res 2006, 39: 1041-55.
26. Bustos P, da Silva AA, Amigo H, et al. Metabolic syndrome in young adults from two socioeconomic Latin American settings. Nutr Metab Cardiovasc Dis 2007, 17: 581-9.
27. Mion D Jr, Machado CA, Gomes MAM, et al. IV Brazilian Guidelines on Arterial Hypertension. Arq Bras Cardiol 2004, 82: 1-22.
28. Hense HW, Koivisto AM, Kuulasmaa K, et al. Assessment of blood pressure measurement quality in the baseline surveys of the WHO MONICA project. J Hum Hypertens 1995, 9: 935-46.
29. Chobanian AV, Bakris GL, Black HR, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003, 289: 2560-72.
30. Matthews DR, Hosker JP, Rudenski AS, et al. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985, 28: 412-9.
31. Arai K, Tsigos C, Suzuki Y, et al. Physiological and molecular aspects of mineralocorticoid receptor action in pseudohypoaldosteronism: a responsiveness test and therapy. J Clin Endocrinol Metab 1994, 79: 1019-23. (Pubitemid 24342241)
32. Ludwig M, Bolkenius U, Wickert L, et al. Common polymorphisms in genes encoding the human mineralocorticoid receptor and the human amiloride-sensitive sodium channel. J Steroid Biochem Mol Biol 1998, 64: 227-30.
33. Silva LM, Silva RA, Silva AA, et al. Racial inequalities and perinatal health in the southeast region of Brazil. Braz J Med Biol Res 2007, 40: 1187-94.
34. Viengchareun S, Le Menuet D, Martinerie L, et al. The mineralocorticoid receptor: insights into its molecular and (pathophysiological biology. Nucl Recept Signal 2007, 530: 5-12.
35. Fuse H, Kitagawa H, Kato S. Characterization of transactivational property and coactivator mediation of rat mineralocorticoid receptor activation function-1 (AF-1). Mol Endocrinol 2000, 14: 889-99.
36. Tallec LP, Kirsh O, Lecomte MC, et al. Protein inhibitor of activated signal transducer and activator of transcription 1 interacts with the N-terminal domain of mineralocorticoid receptor and represses its transcriptional activity: implication of small ubiquitin-related modifier 1 modification. Mol Endocrinol 2003, 17: 2529-42.
37. Funder JW. Mineralocorticoid receptors: distribution and activation. Heart Fail Rev 2005, 10: 15-22.
38. Spencer RL, Kim PJ, Kalman BA, Cole MA. Evidence for mineralocorticoid receptor facilitation of glucocorticoid receptor-dependent regulation of hypothalamic-pituitary-adrenal axis activity. Endocrinology 1998, 139: 2718-26.
39. Young EA, Lopez JF, Murphy-Weinberg V, et al. The role of mineralocorticoid receptors in hypothalamic-pituitary-adrenal axis regulation in humans. J Clin Endocrinol Metab 1998, 83: 3339-45.
40. Heuser I, Deuschle M, Weber A, et al. The role of mineralocorticoid receptors in the circadian activity of the human hypothalamus-pituitary-adrenal system: effect of age. Neurobiol Aging 2000, 21: 585-9.